Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs June Health

Direct Meds
Graded #19

Higher grade

vs+19.599999999999994
June Health
Graded #261

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 63/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +24
85
61
Dose & formulationDirect Meds +13
88
75
Clinical oversightDirect Meds +21
80
59
Labs & monitoringDirect Meds +27
78
51
FulfillmentDirect Meds +6
80
74
Contract termsDirect Meds +25
80
55
Direct Meds · left barJune Health · right bar

The numbers

MetricDirect MedsJune Health
WeighScore82.6/10063/100
GradeB−C
Scorecard rank#19#261
Semaglutide$179/mo$179/mo (starting dose, compounded)
Tirzepatide$224/mo$179/mo (starting dose, compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard